معرفی
Hanna Eriksson is an Associate Professor at the Department of Oncology-Pathology, Karolinska Institutet, where she leads the Clinical and Translational Melanoma Research Group. Her work bridges clinical decision-making and translational research, leveraging large-scale register data, artificial intelligence, and multi-omics analyses within clinical trials.
Her research focuses on:
- Immune-tumor microenvironment interactions
- Overcoming immunotherapy resistance
- Real-world melanoma treatment outcomes
- Gender differences in immunotherapy side effects
- Development of quality of life modules for advanced melanoma
Key trends in her 2025–2021 publications include tumor heterogeneity in brain metastases, adjuvant immunotherapy optimization, plasma proteomics, and biomarkers for immune checkpoint inhibitors. Her group explores AI integration in diagnostics and precision medicine strategies.
She supervises PhD students and postdocs, and has secured grants from:
- Swedish Research Council
- Swedish Cancer Society
- Horizon 2020 (GenderNet-Plus)
- Radiumhemmet Research Funds
- Stockholm Regional Council
- Karolinska Institutet Translational Seed Funding
Her team collaborates on trials like G-DEFINER (gender-specific immunotherapy toxicities) and AIDMel (AI in melanoma diagnostics), emphasizing real-world data and multi-omics approaches.
